Davis Polk advised AstraZeneca PLC in connection with its SEC-registered shelf takedown of $1.2 billion aggregate principal amount of 0.700% notes due 2026, $1.3 billion aggregate principal amount of 1.375% notes due 2030 and $500 million aggregate principal amount of 2.125% notes due 2050.
AstraZeneca is a global, science-led, patient-focused pharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: oncology; cardiovascular, renal and metabolism; and respiratory and immunology.
The Davis Polk corporate team included partner Leo Borchardt and associates Andrew Rowe and Maxim Van de moortel. Counsel Alon Gurfinkel and associate Summer Xia provided tax advice. Partner Gregory S. Rowland and associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the London and New York offices.